Cargando…

Causes and Consequences of miR-150-5p Dysregulation in Myasthenia Gravis

Autoimmune Myasthenia gravis (MG) is a chronic neuromuscular disease mainly due to antibodies against the acetylcholine receptor (AChR) at the neuromuscular junction that induce invalidating muscle weaknesses. In early-onset MG, the thymus is the effector organ and is often characterized by B-cell i...

Descripción completa

Detalles Bibliográficos
Autores principales: Cron, Mélanie A., Maillard, Solène, Truffault, Frédérique, Gualeni, Ambra Vittoria, Gloghini, Annunziata, Fadel, Elie, Guihaire, Julien, Behin, Anthony, Berrih-Aknin, Sonia, Le Panse, Rozen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6450174/
https://www.ncbi.nlm.nih.gov/pubmed/30984166
http://dx.doi.org/10.3389/fimmu.2019.00539
_version_ 1783408987842019328
author Cron, Mélanie A.
Maillard, Solène
Truffault, Frédérique
Gualeni, Ambra Vittoria
Gloghini, Annunziata
Fadel, Elie
Guihaire, Julien
Behin, Anthony
Berrih-Aknin, Sonia
Le Panse, Rozen
author_facet Cron, Mélanie A.
Maillard, Solène
Truffault, Frédérique
Gualeni, Ambra Vittoria
Gloghini, Annunziata
Fadel, Elie
Guihaire, Julien
Behin, Anthony
Berrih-Aknin, Sonia
Le Panse, Rozen
author_sort Cron, Mélanie A.
collection PubMed
description Autoimmune Myasthenia gravis (MG) is a chronic neuromuscular disease mainly due to antibodies against the acetylcholine receptor (AChR) at the neuromuscular junction that induce invalidating muscle weaknesses. In early-onset MG, the thymus is the effector organ and is often characterized by B-cell infiltrations leading to ectopic germinal center (GC) development. The microRNA miR-150-5p has been previously characterized as a biomarker in MG due to its increase in the serum of patients and its decrease after thymectomy, correlated with an improvement of symptoms. Here, we investigated the causes and consequences of the miR-150 increase in the serum of early-onset MG patients. We observed that miR-150 expression was upregulated in MG thymuses in correlation with the presence of thymic B cells and showed by in situ hybridization experiments, that miR-150 was mainly expressed by cells of the mantle zone of GCs. However, we did not observe any correlation between the degree of thymic hyperplasia and the serum levels in MG patients. In parallel, we also investigated the expression of miR-150 in peripheral blood mononuclear cells (PBMCs) from MG patients. We observed that miR-150 was down-regulated, especially in CD4(+) T cells compared to controls. These results suggest that the increased serum levels of miR-150 could result from a release from activated peripheral CD4(+) T cells. Next, we demonstrated that the in vitro treatment of PBMCs with miR-150 or antimiR-150 oligonucleotides, respectively, decreased or increased the expression of one of its major target gene: the proto-oncogene MYB, a well-known actor of hematopoiesis. These results revealed that increased serum levels of miR-150 in MG patients could have a functional effect on PBMCs. We also showed that antimiR-150 caused increased cellular death of CD4(+) and CD8(+) T cells, along with the overexpression of pro-apoptotic genes targeted by miR-150 suggesting that miR-150 controlled the survival of these cells. Altogether, these results showed that miR-150 could play a role in MG both at the thymic level and in periphery by modulating the expression of target genes and peripheral cell survival.
format Online
Article
Text
id pubmed-6450174
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-64501742019-04-12 Causes and Consequences of miR-150-5p Dysregulation in Myasthenia Gravis Cron, Mélanie A. Maillard, Solène Truffault, Frédérique Gualeni, Ambra Vittoria Gloghini, Annunziata Fadel, Elie Guihaire, Julien Behin, Anthony Berrih-Aknin, Sonia Le Panse, Rozen Front Immunol Immunology Autoimmune Myasthenia gravis (MG) is a chronic neuromuscular disease mainly due to antibodies against the acetylcholine receptor (AChR) at the neuromuscular junction that induce invalidating muscle weaknesses. In early-onset MG, the thymus is the effector organ and is often characterized by B-cell infiltrations leading to ectopic germinal center (GC) development. The microRNA miR-150-5p has been previously characterized as a biomarker in MG due to its increase in the serum of patients and its decrease after thymectomy, correlated with an improvement of symptoms. Here, we investigated the causes and consequences of the miR-150 increase in the serum of early-onset MG patients. We observed that miR-150 expression was upregulated in MG thymuses in correlation with the presence of thymic B cells and showed by in situ hybridization experiments, that miR-150 was mainly expressed by cells of the mantle zone of GCs. However, we did not observe any correlation between the degree of thymic hyperplasia and the serum levels in MG patients. In parallel, we also investigated the expression of miR-150 in peripheral blood mononuclear cells (PBMCs) from MG patients. We observed that miR-150 was down-regulated, especially in CD4(+) T cells compared to controls. These results suggest that the increased serum levels of miR-150 could result from a release from activated peripheral CD4(+) T cells. Next, we demonstrated that the in vitro treatment of PBMCs with miR-150 or antimiR-150 oligonucleotides, respectively, decreased or increased the expression of one of its major target gene: the proto-oncogene MYB, a well-known actor of hematopoiesis. These results revealed that increased serum levels of miR-150 in MG patients could have a functional effect on PBMCs. We also showed that antimiR-150 caused increased cellular death of CD4(+) and CD8(+) T cells, along with the overexpression of pro-apoptotic genes targeted by miR-150 suggesting that miR-150 controlled the survival of these cells. Altogether, these results showed that miR-150 could play a role in MG both at the thymic level and in periphery by modulating the expression of target genes and peripheral cell survival. Frontiers Media S.A. 2019-03-29 /pmc/articles/PMC6450174/ /pubmed/30984166 http://dx.doi.org/10.3389/fimmu.2019.00539 Text en Copyright © 2019 Cron, Maillard, Truffault, Gualeni, Gloghini, Fadel, Guihaire, Behin, Berrih-Aknin and Le Panse. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Cron, Mélanie A.
Maillard, Solène
Truffault, Frédérique
Gualeni, Ambra Vittoria
Gloghini, Annunziata
Fadel, Elie
Guihaire, Julien
Behin, Anthony
Berrih-Aknin, Sonia
Le Panse, Rozen
Causes and Consequences of miR-150-5p Dysregulation in Myasthenia Gravis
title Causes and Consequences of miR-150-5p Dysregulation in Myasthenia Gravis
title_full Causes and Consequences of miR-150-5p Dysregulation in Myasthenia Gravis
title_fullStr Causes and Consequences of miR-150-5p Dysregulation in Myasthenia Gravis
title_full_unstemmed Causes and Consequences of miR-150-5p Dysregulation in Myasthenia Gravis
title_short Causes and Consequences of miR-150-5p Dysregulation in Myasthenia Gravis
title_sort causes and consequences of mir-150-5p dysregulation in myasthenia gravis
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6450174/
https://www.ncbi.nlm.nih.gov/pubmed/30984166
http://dx.doi.org/10.3389/fimmu.2019.00539
work_keys_str_mv AT cronmelaniea causesandconsequencesofmir1505pdysregulationinmyastheniagravis
AT maillardsolene causesandconsequencesofmir1505pdysregulationinmyastheniagravis
AT truffaultfrederique causesandconsequencesofmir1505pdysregulationinmyastheniagravis
AT gualeniambravittoria causesandconsequencesofmir1505pdysregulationinmyastheniagravis
AT gloghiniannunziata causesandconsequencesofmir1505pdysregulationinmyastheniagravis
AT fadelelie causesandconsequencesofmir1505pdysregulationinmyastheniagravis
AT guihairejulien causesandconsequencesofmir1505pdysregulationinmyastheniagravis
AT behinanthony causesandconsequencesofmir1505pdysregulationinmyastheniagravis
AT berrihakninsonia causesandconsequencesofmir1505pdysregulationinmyastheniagravis
AT lepanserozen causesandconsequencesofmir1505pdysregulationinmyastheniagravis